company background image
IMU

Imugene ASX:IMU Stock Report

Last Price

AU$0.20

Market Cap

AU$1.2b

7D

14.7%

1Y

-58.5%

Updated

25 May, 2022

Data

Company Financials +
IMU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMU Stock Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.

Imugene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share PriceAU$0.20
52 Week HighAU$0.63
52 Week LowAU$0.15
Beta2.26
1 Month Change-13.33%
3 Month Change-11.36%
1 Year Change-58.51%
3 Year Change1,047.06%
5 Year Change1,400.23%
Change since IPO100.00%

Recent News & Updates

Shareholder Returns

IMUAU BiotechsAU Market
7D14.7%0.5%-1.2%
1Y-58.5%-8.0%-0.009%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -8% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement13.4%
Biotechs Industry Average Movement9.9%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: IMU is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IMU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1986n/aLeslie Chonghttps://www.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.

Imugene Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market CapAU$1.20b
Earnings (TTM)-AU$27.22m
Revenue (TTM)AU$8.49m

134.5x

P/S Ratio

-41.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMU income statement (TTM)
RevenueAU$8.49m
Cost of RevenueAU$0
Gross ProfitAU$8.49m
Other ExpensesAU$35.72m
Earnings-AU$27.22m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0046
Gross Margin100.00%
Net Profit Margin-320.60%
Debt/Equity Ratio0%

How did IMU perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Imugene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-1.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMU's revenue (20.2% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: IMU's revenue (20.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IMU is forecast to be unprofitable in 3 years.


Past Performance

How has Imugene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-44.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMU is currently unprofitable.

Growing Profit Margin: IMU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).


Return on Equity

High ROE: IMU has a negative Return on Equity (-17.95%), as it is currently unprofitable.


Financial Health

How is Imugene's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMU's short term assets (A$125.3M) exceed its short term liabilities (A$6.7M).

Long Term Liabilities: IMU's short term assets (A$125.3M) exceed its long term liabilities (A$1.1M).


Debt to Equity History and Analysis

Debt Level: IMU is debt free.

Reducing Debt: IMU has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMU has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 37.9% each year


Dividend

What is Imugene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMU has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Leslie Chong

5.5yrs

Tenure

AU$789,284

Compensation

Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...


CEO Compensation Analysis

Compensation vs Market: Leslie's total compensation ($USD557.96K) is below average for companies of similar size in the Australian market ($USD1.03M).

Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IMU's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: IMU's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.


Top Shareholders

Company Information

Imugene Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Imugene Limited
  • Ticker: IMU
  • Exchange: ASX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$1.199b
  • Shares outstanding: 5.85b
  • Website: https://www.imugene.com

Location

  • Imugene Limited
  • 37 Bligh Street
  • SUITE 804
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.